5 курс / Пульмонология и фтизиатрия / Бронхолегочные_осложнения_хронических_лейкозов

425.Keats J.J., Reiman T., Maxwell C.A. In multiple myeloma, t (4; 14) (p16:q32) is an adverse is adverse prognostic factor irrespective of FGFR3 expression // Blood. – 2003. – P. – 1520 – 1529.

426.Kellogg D. L. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges // J. apl. Physiol. – 2006. – Vol. 100. – P. 1709–1718.

427.Kempf F., Capesing P., Mugel J.L. Un cas de calcinose pulmonaire au cours d’une myelomatose diffuse // J. Radiol. Electrol. – 1972. – Vol. 53, N 12. – P. 861–865.

428.Khouri I.F., Munsell M., Yajzi S. Comparable survival for nonablative and ablative alloggeneic transplantation for chronic lymphocytic leukemia: the case for early intervention // Blood. – 2000. – Vol. 96. – P. 205a.

429.Kienle, D.L. The spleen in hematologic malignancies. / DL Kienle. //Ther Umsch. – 2013. - 70(3).- P. 163-169.

430.Kohl F.V., Wicher P. Hochduch in lungenkreislaut Therapeutische Moglechakeiten // Thrapiewocye. – 1986. – Vol. 36, N 9. – P. 2024–2030.

431.Kotner L.M., Wang C.C. Plasmacytoma of the Upper Air and Food Passages // Cancer. – 1972. – Vol. 30, N 2. – P. 414–418.

432.Kraj M., Poglod R., Maj S. Comparative evaluation of safety and efficacy of pa-midronate and zoledronic acid in multiple myeloma patients (single center experience) // Acta Pol. Pharm. – 2002. – Vol. 59. – P. 478–482.

433.Kumar S., Fonseca R., Dispenzieri A. Prognostic value of angiogenesis in olitary bone plasmacytoma

// Blood. – 2003. – Vol. 101. – P. 1715–1717.

434.Kutti J., Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis // Pathol. Biol. (Paris). — 2001. — Vol. 49, N 2. — P. 164-166.

435.Kvandal P., Stefanovska A., Veber M. Regulation of human cutaneous circulation evaluated by laser Dopler flowmetry, iontophoresis, and spectral analysis: importance of nitric oxide and prostangladines // Mikrovaskular Research. – 2003. – Vol. 65. – P. 160

– 171.

436.Kvandal P., Stefanovska A., Veber M. Regulation of human cutaneous circulation evaluated by laser Dopler flowmetry, iontophoresis, and spectral analysis: importance of nitric oxide and prostangladines // Mikrovaskular Research. – 2003. – Vol. 65. – P. 160

– 171.

437.Kyle R. A., Gertz M.A., Witzig T.E. Review of 1027 patients with newly diagnosed multiple myeloma // Mayo Clin. Proc. – 2003. – Vol. 78, N 1. – P. 21–33.

438.Laboratory investigations in clinical immunology: methods, pitfalls, and clinical indications. A second IUIS/WHO report // Clin. Immunol. Immunopathol.

– 1988. – Vol. 49. – P. 478–497.

439.Lamour, C. Non-infectious pulmonary complications of myelodysplastic syndromes and chronic myeloproliferative disorders / C. Lamour, A. Bergeron // Rev Mal Respir. – 2011. - 28(6). – P. 18-27.

440.Lebecque, P. Hysteresis of the alveolar capillary membrane in normal subjects // J. Appl. Physiol. – 1986. – Vol. 60, N 6. – P. 1442–1445.

441.Lee C.K., Ma E.S., Shek T.W. Plasmablastic transformation of multiple myeloma // Hum. Pathol. – 2003. – Vol. 34, N 7. – P. 710–714.

442.Leporrier M., Chevret S., Casin B. Randomized comparison of fludarabine, CAP and CHOP in 938 previously untreated stage B and C chronic lymphocytik leukemia patients // Blood. – 2001. – Vol. 98, N 8. – P. 2319–2325.

443.Leukemic infiltration of the lung following allogeneic hematopoietic stem cell transplantation / K. Kakihana, K. Ohashi, F. Sakai [et al.] //. Internal Journal of Hematology. - 2009. – Vol.89, No.1. – P.118122.

444.Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia / V. De Stefano, T. Za, E. Rossi [et al.] // American Journal of Hematology. – 2010. - 85(2). - P. 97-100.

445.Leventakos, K. Fungal infections in leukemia patients: how do we prevent and treat them? / K. Leventakos, RE. Lewis, DP/ Kontoyiannis // Clin Infect Dis. – 2010. - 50(3). – P. 405-415.

446.Levine R.A., Gibson T.S., Aretz T. Echocardiographic measurement of right ventricular volume // Circulation. – 1984. – Vol. 69. – P. 497–505.

447.Ligriti obstrukcio es az arteria pulmonalis hyomasa Kozotti osseufugyei terheles alatt / L. Meszaros [et al.] // Pneumol. hung. – 1983. – Vol. 36, N 6. – P.

266–272.

448.Lim Y., Park S.R., Oh H.S. A case of primary plasmacytoma of lymph nodes // J. Intern. Med. – 2005. – Vol. 20, N 2. – P. 183–186.

449.Lindsley H., Teller D., Nonnan B. Hyperviscosity syndrome in multiple myeloma. A reversille, concentration – dependent aggregation of the myeloma protein // Amer. J. M. et al. – 1973. – Vol. 54, N 5. – P. 682–688.

450.Linet M. S., Blattner W.A. Chronic Lymphocyte Leukemia // Switz., 1988. – P. 11–15.

451.Lipton А., Small E., Saad F. he new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesion: a comparison to pamidronate // Cancer Invest. – 2002.

– Vol. 20, Supl. 2. – P. 45–54.

452.Livermore D.M., Canton R., Gniadkowski M. X-M: changing the face of ESBLs in Europe // J. Antimicrob. Chemother. – 2007. – Vol. 59, N. 2. – P. 165– 174.

453.Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis / L. Camba, L. Aldrighetti, F. Ciceri [et al.] // Br. J. Haematol. — 2001. — Vol. 114, N3. — P. 638-640.

454.Low diagnostic yield of bronchoscopy in nonresolving pneumonia of patients with hematologic neoplasms / S. Ewig, K. H. Nachtsheim, R. Schumacher [et al.] // European respiratory journal. - 1995. - Vol. 8. - Suppl.19. - P. 1194.

455.Ma M.N., Yang H.H. Раrker he proteasome inhibitor PS – 341 markedly enhances sensitivity of multiple

myeloma tumor cells chemotherapeutic agents // Clin. Cancer Res – 2003. – P. – 1136 – 1144.

456.Machado R.F., Farber H.W. Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders // Clinics in Chest Medicine. – 2013.

– Dec, 34(4). – P. 739-752.

457.Maisnar V., Touskova M., Maly J. Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma // Vnitr. Lek. – 2002. – Vol. 48. – P. 209–297.

458.Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera / M. Karakantza, NC Giannakoulas, P. Zikos [et al.] // International Journal of Hematology.

– 2004. - 79(3). – P. 253-259.

459.Menssen H.D., Sacalova A., Fontana A. Effects of long-term intravenous ibandronate therapy on skele- tal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

//J. Clin. Oncol. – 2002. – Vol. 20. – P. 2353–2359. 460.Mesa R. A., Tefferi A. Palliative splenectomy in

myelofibrosis with myeloid metaplasia // Leukemia Lymphoma. — 2001. — Vol. 42, N 5. — P. 901911.

461.Milkowski D.A., Worley B.D., Morris M.J. Richter's transformation presenting as an obstructing endobronchial lesion // Chest. – 1999. – Vol. 116, N 3. – P. 832–837.

462.Mitsiades N., Mitsiades C.D., Richardson P.G. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications // Blood.

– 2003. – Vol. 101. – P. 2377–2380.

463.Mital O.P., Gupta D.K., Kansal H. M. Intrathoracic muelomatosis : a case report // Indian J. Chest. Dis.

– 1974. – Vol. 16, N 2. – P. 119–120. 464.Montserrat E. Chronic lymphoproliferative disorders

//Curr. Opin. Oncol. – 1997. – Vol. 1. – P. 34–41. 465.Monocytosis is an adverse prognostic factor for sur-

vival in younger patients with primary myelofibrosis / M. A. Elliot, S. Verstovsek, D. Dingli [et al.] // Leukemia Research. – 2007. – 3. – Р.11503-11509.

466.Mozzaffari E., Mupparpu M., Otis L. Undiagnosed multiple myeloma causing extensite dental bleeding: report of a case and review // Oral Surg. Oral. Med. Oral. Radiol. Endod. – 2002. – Vol. 94. – P. 448– 453.

467.Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. / T.Mughal, K. Vaddi, NJ. Sarlis, S.Verstovsek // International Journal of General Medicine. – 2014. - Jan 29. – P. 89-101.

468.Myelofibrosis-associated massive splenomegaly: a cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea / PD. Ziakas, M.Voulgarelis [et al] //American Journal of Hematology. – 2005. - 80(2). - P. 128-132.

469.Muller N.L., Chiles C., Kullnig P. Pulmonary lym- phongiomyomutosis-correlation CT with radiographic and functional findings // Radiology. – 1990. – Vol. 175. – P. 535–539.

470.Muller P.S., Terrell C.L., Gertz M.A. Fever of unknown origin caused by multiple myeloma: a report of 9 cases // Arch. Intern. Med. – 2002. – Vol. 162. – P. 1305–1309.

471.Multiple myeloma and chronic lymphocytic leukemia / R. Vescio [et al.] // Curr. Opin. Hematol. – 1996. – Vol. 3, N 4. – P. 288–296.

472.Multiple myeloma with pleural involvement / P. Badrinas [et al.] // Amer. Rev. Resp. Dis. – 1974. – Vol. 110, N 1. – P. 82–87.

473.Murphy, T. F. The role of bacteria in airway in inflammation in exacerbations of chronic obstructive pulmonary disease. Pathogenesis and immune response // Cur. Opinion Infect. Dis. – 2006. – Vol. 19, N 3. – P. 225–230.

474.Nagasava T., Abe T., Nakagava T. Pure red cell aplasia and hypogammaglobulinemia assotiated with T-cell CLL // Blood. – 1981. – Vol. 57, N 6. – P. 1025–1031.

475.Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms / G. Cella, M. Marchetti, F. Vianello [et al.] // Journal of Thrombosis and Haemostasis. – 2010. - 104(1). – P. 151-156.

476.Nosocomial pneumonias in haematological malignancies in the medical intensive care unit / G. Hoheisel, S. Lange, J. Winkler [et al.] // Pneumologie. - 2003. - Vol. 57. - N 2. - P. 73-77.

477.Nucci M., Anaissie E. Cutaneus infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management // Clin. Infect. Dis. – 2002. – Vol. 35. – P. 909–920.

478.Oikonomou A., Muller N.L., Nantel S. Radiographic and high-resolution CT findings of influenza virus pneumonia in patients with hematologic malignancies // Am. J. Roentgenol. – 2003. – Vol. 181, N 2. – P. 507–518.

479.Orchard K., Barrington S., Buskombe J. Fluorodeoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma // Br. J. Haematol. – 2002. – Vol. 117.

– P. 133–135.

480.Osserman E.F., Di Re L.B. Identical twin marrow transplantation in multiple myeloma // Acta Hematol.

– 1982. – Vol. 68. – P. 215–223.

481.Overcoming the problem of pseudohypoxemia in myeloproliferative disorders / KN. Prasad, P. Manjunath, L. Priya [et al.] // Indian Journal of Critical Care Medicine. – 2012. - 16(4). – P. 210-212.

482.Pahor A. L. Plasmacytoma of the Larynz // J. Laryng. – 1978. – Vol. 92, N 3. – P. 225–232.

483.Panidis J.P., Ross J., Mintz G.S. The effect of sampling site on the assessment of pulmonary blood flow by doppler echocardiography // 10 World Congress of Cardiology, Washington, 14-19 Sept. 1986. – Washington, 1986. – P. 277.

484.Parapneumonic effusions / R.W. Light [et al.] // Amer. J. Med. – 1980. – Vol. 69. – P. 507–511.

485.Pastor F.J. Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections // Clin. Microbiol. Infect. – 2006. – Vol. 12, N 10. – P. 948–960.

486.Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice / F. Santoleri, P. Sorice, R. Lasala [et al.] // PLoS One. – 2013. -8(2) -

56813.

487.Piragine F. I. Рlasmocitomi solitari extramidollari nei distretti O.R.L. // Atenco parmensc. – 1974. – Vol. 45, N 3. – P. 131–144.

488.Platelet abnormalities in idiopathic myelofibrosis: functional, biochemical and immunomorphological correlations / P. Leoni, S. Rupoli, [et al.] // Haematology. - 1994. - Vol. 79. - P. 29-39.

489.Polizzotto M.N., Tam C.S., Milner A. The influence of increasing age on the deliverability and toxity of fludarabine-based combination chemotherapy regi-

ment in patients with indolent limfoproliferative disorders // Cancer. – 2006. – Vol. 107, N 5, Aug. 15. – P. 773–780.

490.Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan / A. Kreft, C. Nolde, G. Busche [et al.] // European Journal of Haematology. — 2000. — Vol. 64, N 1. — P. 32-41.

491.Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment / T. C. Pearson, M. Messinezy, N. Westwood [et al.] // Hematology.— 2000. — P. 5168.

492.Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera / A. Falanga, M. Marchetti, V. Evangelista [et al.] // Blood. – 2000. - 96(13). – P. 4261-4266.

493.Prchal, JT. Treatment target in polycythemia vera / JT Prchal, VR. Gordeuk // N Engl J Med. – 2013. - 368(16). –P. 1555-1556.

494.Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) / R. A.Mesa , S. Verstovsek [et al.] // Leukemia Research. – 2007. – 31. – Р.737-740.

495.Prognostic factors and survival in chronic myeloproliferative disorders / H. M. Kvasnicka, J.Thiele, A. Schmitt-Graeff, H. Schaefer E. // Pathologe. - 2000. - Vol. 21, N 1. - P. 63-72.

496.Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system / В. Dupriez, P. Morel, J. L. Demory [et al.] // Blood. — 1996. —Vol. 88. —P. 1013-1018.

497.Progress in understanding myeloproliferative neoplasms / A. Vannuchi, P. Gudlielmelti, A. Tefferi [et al.] // Cancer Journal Clinical. - 2009. - 59. - P. 171191.

498.Pulmonary arterial hypertension and emphysema / I. P. Williams [et al.] // Brit. J. Dis. Chest. – 1984. – Vol. 78, N 3. – P. 211–216.

499.Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia - critical alert / M. Sano, M.Saotome, T. Urushida [et al.] // Intern Med. – 2012. - 51(17). – P. 2337-2340.

500.Pulmonary complications in liver diseases. / T. Horvatits, A. Drolz, K. Rutter [et al.] // Med Klin Intensivmed Notfmed. - 2014. - Apr 26.

501.Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU / S. Ewig, A. Torres, R. Riquelme [et al.] // European respiratory journal. - 1998. - Vol. 12. - N l.- P. 11622.

502.Pulmonary infiltrates in immunosuppressed patients: analysis of a diagnostic protocol / C. Danes, J. Gon- zales-Martin, Т. Pumarola [et al.] // The Journal of Clinical Microbiology. - 2002. - Vol. 40. - N 6. - P. 2134 - 2140.

503.Pulmonary involvement as the major manifestation of chronic lymphocytic leukemia / N. Berkman [et al.] // Leuk. Lymphoma. – 1992.– Vol. 8, N 6. – P. 495–499.

504.Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison / KM Phillips, J. Pinil- la-Ibarz, E. Sotomayor [et al.] // Support Care Cancer. -2013. -21(4). – P.1097-1103.

505.Rai K.R., Savitsky A., Crenkite E.P. Clinical staging of chronic lymphocytic leukemia // Blood. – 1975. – Vol. 46. – P. 219–234.

506.Rajkumar, S.V. Ask the Expert // Myeloma Focus. – 2002. – Vol. 3. – P. 43–48.

507.Rajkumar S.V., Hauman S., Gertz M.A. Combination therapy with thalidomide plus dexamethasone fo newly diagnosed myeloma // J. Clin. Oncol. – 2002.

– P. – 4319 – 4323.

508.Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy / S. Mustjoki, K. Auvinen [et al.] // Leukemia. – 2013. - 27(4). – P. 914-924.

509.Reikvam H. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera / H. Reikvam, R.V. Tiu // Leukemia. – 2012. - 26(4).- P. 387-397.

510.Remy-Jardin M., Jiraud F., Remy J. Importance of graund-glass attenuation in chronic infiltrative lung disease-pathologic CT correlation // Radiology. – 1993. – 1989. – P. 603–698.

511.Respiratory syncytial virus, airway inflammation, and fev1 decline in patients with chronic obstructive pulmonary disease / T. M. A. Wilkinson [et al.] // Am. J. Respire. Crit. Care Med. – 2006. – Vol. 173.

– P. 871–876.

512.Risk factor and clinical features of nosocomial pneumonias / Yu. S. Landyshev [et al.] // IV Russia and China Medical Forum : abstracts. – Blagoveschensk, 2007. – P. 114–116.

513.Rochester D.F. Respiratory muscles and ventilatory failure: 1993 perspective // Am. J. Med. Sci. – 1993.

– Vol. 305. – P. 394–402.

514.Rochester, D. F. Respiratory muscles and ventilatory failure: 1993 perspective / D. F. Rochester // American Journal of the Medical Sciences. – 1993. – Vol. 305. – P. 394–402.

515.Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. / X. Tan, J Shi, Y Fu. [et all.] // Thrombosis and Haemostasis. – 2013. - 109(6).

516.Rodriguez C., Lujan-Zilbermann J., Woodard P. Successful treatment of disseminated fusariosis // Bone Marrow Transplant. – 2003. – Vol. 31. – P. 411–412.

517.Rollins S D., Colby T.V. Lung biopsy in chronic lymphocytic leukemia // Arch . Pathol. Lab. Med. – 1988. – Vol. 112, N 6, Jun. – P. 607–611.

518.Rome L., Murali G. , M. Lippmann Nonresolving pneumonia and mimics of pneumonia // Med. Clin. Am. – 2001. – N 85. – P. 1511–1530.

519.Sadek S.A. Plasmacytoma of the nasopharynx // J. Laryngol otol. – 1985. – Vol. 99, N 12. – P. 1289– 1292.

520.Santra M.A., Zhan F., Tian E. Subsect of multiple myeloma harboring the t(4; 14) (p16; q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript // Blood. – 2003. – Vol. 101. – P. 2374–2376.

521.Sanz L., Blade J., Olondo M. Contribution of magnetic resonance to the differential diagnosis of a collapsed vertebra in a patient with multiple myeloma // Sangre (Bark). – 1998. – Vol. 43. – P. 77–81.

522.Saubolle M.A., Saubolle M.A., Sussland D. Nocardiosis: review of clinical and laboratory experience // J. Clin. Microbiol. – 2003. – Vol. 41. – P. 4497– 4501.

523.Schlenkhoff C.D., Heuser L.J. Pulmonary edema in pulmonary leukostasis in acute myeloid leukemia // Rofo. -2012. - 184(9).- P. 832-834.

524.Schulmmer P., Heise D. Die klinische konseguenz des Euler lifiesraud mechanism bei obstruktiver ventilationsstorueg // Therapiewoche. – 1984. – Bd. 34, N 47. – S. 6718–6726.

525.Schulz H., Rehward U. Phase 2 study of combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia // Blood. – 2002. – Vol. 10. – P. 3115–3120.

526.Schulz H., Wendtner C.M., Bergmann M. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia // Clin. Lymphoma. – 2002. – Vol. 3. – P. 26–35.

527.Schwaenen C., Nessling M., Wessendorf S. Automated array-based genomic profiling in chronic lumphocytic leykemia: Development of a clinical tool and discovery of recyrrent genomic alterations // Proc. Natl. Acad. Sci. USA. – 2003. – Vol. 101. – P. 1039–1044.

528.Sekulich M., Pandola A. Solitary pulmonary mass multiple myeloma // Dis. chest. – 1965. – Vol. 48, N 1. – P. 100–103.

529.Seneterre E., Paganin F., Bruel J.M. Measurement of the internal size of bronchi high resolution computed tomography // Eur. Respir. J. – 1994. – Vol. 7. – P. 596–600.

530.Siafakas N. M. ERS Consensus Statement: optimal assessment and management of chronic obstructive pulmonary disease // Eur. Respir. Rev. – 1996. – Vol. 6, N 39. – P. 270–275.

531.Simoneau, CA. Treating chronic myeloid leukemia: improving management through understanding of the patient experience / CA. Simoneau // Clin J Oncol Nurs. – 2013. - 17(1). – P. 13-20.

532.Singhal S. Hight-dose therapi and autologous transplantation // Myeloma. – 2002. – 2002. – P. 327 – 347.

533.Slungaard A., Smith M.J. Serum immunoglobulin levels in chronic lymphatic leukemia // Scand. J. Haematol. – 1974. – Vol. 12, N 2. – P. 112–116.

534.Smith B.D. Biology and management of idiopathic myelofibrosis / B. D. Smith, A. R. Moliterno // Current Opinion of Oncology. — 2001. — Vol. 13, N 2.

— P. 91-94.

535.Spenser А. The pulmonary plasma cell (histiocytoma complex) / Spenser // H. Histopathology. – 1984. – Vol. 8, N 6. – P. 903–916.

536.Spicka I., Cieslar P., Prochazka B. Prognostic factors and marcers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and treatment of Multiple Myeloma) // Cas. Lek. Cesk. – 2000. – Vol. 139. – P. 208–212.

537.Spicka I., Klener P. Multiple Myeloma – clinical symptoms, diagnosis, prognosis, therapy // Cas. Lek. Cesk. – 2000. – Vol. 139. – P. 391–395.

538.Spivak ,J. L. Polycythemia vera: myths, mechanisms, and management / J. Spivak // Blood. - 2002. - 100(13). – P. 4272-4290.

539.Spivak J.L. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal / J. L. Spivak , R.T.Silver // Blood. – 2008. -112. – P. 231-239.

540.Stein BL. Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms / BL. Stein, RV. Tiu // Journal Interferon Cytokine Res. – 2013. - 33(4).- P. 145-153.

541.Stevens D., Kan V., Jidson M. Practice guidelines for diseases caused by Aspergillus // Clin. Inf. Dis.

– 2000. – Vol. 30. – P. 662–679.

542.Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP / M. Penka, J. Schwarz,

V.Campr [et al.] // Vnitrní Lékarství. – 2012. 58(2). – P. 163168.

543.Sur les manifestations T.F. thoraciques au cours de la maladie de Kahle / R. Pieron [et al.] // Poumon. – 1972. – Vol. 28, N 8. – P. 427–434.

544.Systematic review of dasatinib in chronic myeloid leukemia / M. Breccia, A. Salaroli [et al.] // Onco Targets Ther. - 2013. - №6. - P. 257-265.

545.Tang X. P., Tian Z., Zhang D. Activating blood circulation and removing stasis in treating polycythemia vera: clinical observation and therapeutical mechanism // Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. - 1997. - Vol. 17, № 1. - P. 20-22.

546.Tefferi A. The pathogenesis of chronic myeloproliferative diseases // Internal Journal of Hematology. - 2001. - Vol. 73, N 2. - P. 170-176.

547.Tefferi A., Vardiman J.W. Classification and of myeloproliferative neoplasms: Tye 2008 World Health Organization criteria and point-of care diagnostic algotryms // Leukemia. – 2008.- 22. – P. 14-22.

548.Tefferi A. The history of myeloproliferative disorders: before and after Dameshek // Leukemia. - 2008. - 22. – P.3-1.

549.Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management // Amer-

ican Journal of Hematology. – 2013. - 88(2).- P. 141150.

550.Tenholder M.J., Scialla S.J., G. Weisbaum Endobronchial metastatic plasmacytoma // USA Cancer. – 1982. – Vol. 49, N 7. – P. 1465–1468.

551.Terwort H. Endotracheal gelegenes Plasmacytom // Fortschr. Rontgesstr. – 1973. – Vol. 119, N 3. – P. 361–362.

552.The cardiopulmonary unit. The body’s gas transport system / K. T. Weber [et al.] // Clin. Chest. Med. – 1983. – Vol. 4, N 2. – P. 101–110.

553. Thibault Ph. Les manifestations Thoraciques au cours des hemopathies // Press med. – 1971. – Vol. 79, N 1. – P. 9–10.

554.Treves R., Guionic J.P., Desproges-Gotteren R. Localisations extra-ossenses du myeloma epanchements pleuraux et atteinte cutance // Rhymatologie. – 1979.

– Vol. 31, N 3. – P. 89–94.

555.Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know / A. Casini, F. Boehlen, T. Lecompte [et al.] // Rev Med Suisse. – 2013. - 9(372). – P. 315-318.

556. Tuddenham E.G.D., Whittaker J.A., Bradley J. Hyperviscosity syndrome in IgA multiple myeloma // Brit. J. Haematol. – 1974. – Vol. 27, N 1. – P. 65– 76.

557.T-cell chronic lymphocytic leukaemia with pulmonary involvement and relapsing BOOP / E. Vaiman [et al.] // Eur. Respir. J. – 1999. – Vol. 14, N 2. – P. 471–475.

558.Unexplained pulmonary hypertension in chronic myeloproliferative disorders / D. Dingli, J. P. Utz,

M. J. Krowka [et al.] // Chest. — 2001. — Vol. 120, N 3. — P. 801-808.

559.Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia // Internal and Emergency Medicine. – 2010. - 5(3). – P. 177-184.

560.Vasconcelos Y., Davy F., Levy V. Binet’s stading system and VH genes are independent but complementory prognostic indicators in chronic lymphocytic leukemia // J. Clin. Oncol. – 2003. – Vol. 21. – P. 3928– 3932.

561.Villmow, T. Markers of platelet activation and plate- let-leukocyte interaction in patients with myeloproliferative syndromes / T Villmow, B KemkesMatthes, AC. Matzdorff // Thrombosis Research. – 2002. - 108(2-3).- P. 139-145.

562.Viral findings in adult hematological patients with neutropenia / L. Ohrmalm, M. Wong, C. Aust [et al.] // PLoS One. - 2012. - 7(5). – 36543.

563.Wierda W., S. O’Brian, S. Wen Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia // J. Clin. Oncol. – 2005. – Vol. 23. – P. 4070–4078.

564.Young, JA. Epidemiology and management of infectious complications of contemporary management of chronic leukemias / JA. Young // Infect Disord Drug Targets. – 2011. - 11(1).- P. 3-10.

565.Zham F., Hardin J., Kordsmeier B. Global gene expression profiling of multiple myeloma, monoclonal gammapathy of indeterminet significance, and normal bone marrow plasma cels // Blood. – 2002. – P. 1745 – 1757

566.Zomas A., Dimopoulos M.A Conventional treatment of myeloma // Myeloma. Eds. Mehta J. and Singhal S. London: Martin Dunitz. – 2002. – P. – 313 – 326.

Ад – амплитуда колебаний в дыхательном диапазоне

Ам – амплитуда колебаний в миогенном диапазоне

Ан – амплитуда колебаний в нейрогенном диапазоне

Ас – амплитуда колебаний в кардиальном (сердечном) диапазоне

Аэ – амплитуда колебаний в эндотелиальном диапазоне БАЛ – бронхо-альвеоллярный лаваж

БОД – болезни органов дыхания БМО – большой молекулярный ответ

БЦО – большой цитогенетический ответ ВПО – Вентиляционно-пефузионное отношение ВФЛ – вентиляционная функция легких ДОр – дыхательный объем реографический

ДСК – диастоло-систолический коэффициент ЖЕЛ – жизненная емкость легких ИВТ – индекс Вотчала - Тиффно

ИДКГ – импульсная допплеркардиография ИМФ – идиопатический миелофиброз ИП – истинная полицитемия КДР – конечно-диастолический размер

КСР – конечно-систолический размер КДО – конечно-диастолический объем КСО – конечно-систолический объем КТ – компьютерная томография ЛА – легочная артерия ЛГ – легочная гипертензия

ЛДФ – лазерная допплеровская флоуметрия ЛЖ – левый желудочек МКК – малый круг кровообращения

ММ – множественная миелома МО – минутный объем кровообращения

МОВр – реографический показатель минутного объёма вентиляции МОС 25 -75 – максимальная объемная скорость выдоха

на уровне крупных, средних и мелких бронхов

МПКр – реографический показатель минутного пульсаторного кровотока МЦР – микроциркуляторное русло

ОФВ1 – объем форсированного выдоха за 1 секунду ПЖ – правый желудочек

ПКГО – полный клинико-гематологический ответ ПМ – параметр микрогемоциркуляции ПР – полная ремиссия ПЦО – полный цитогенетический ответ СИ – сердечный индекс

СКр – реографический показатель систолического кровенаполнения СрДЛА – среднее давление в легочной артерии

ССК – средняя скорость кровенаполнения легких ТД – толщина диафрагмы

ТМПСПЖ – толщина миокарда передней стенки ПЖ в диастолу ТМЗСЛЖ – толщина миокарда задней стенки левого же-

лудочка в диастолу ТМЖПД – толщина межжелудочковой перегородки в диастолу УИ – ударный индекс

УО – ударный объем ФВ – фракция выброса

ФВД – функция внешнего дыхания ХЛЛ – хронический лимфолейкоз ХМЛ – хронический миелолейкоз

ХОБЛ – хроническая обструктивная болезнь легких ХЛС – хроническое легочное сердце ХПН – хроническая почечная недостаточность ЧР – частичная ремиссия

ЭДс – экскурсия диафрагмы при спокойном дыхании ЭДф – экскурсия диафрагмы при форсированном дыхании ЭРТГ – электрорентгенотомография

ЭХОКГ – эхокардиография Кv – коэффициент вариации

σ – среднее квадратичное отклонение ПМ РIg – моноклональный иммуноглобулин pH – активность водородных ионов

pCO2 – парциальное давление углекислого газа pO2 – парциальное давление кислорода

AaDO2 – артериально-альвеолярная разница парциального давления О2

O2 sat – насыщение гемоглобина кислородом

O2 cont – общее содержание кислорода, растворённого и связанного в крови